Microbiological and clinical effects of probiotics and antibiotics on nonsurgical treatment of chronic periodontitis: a randomized placebo- controlled trial with 9-month follow-up

Alicia Morales, Alessandro Gandolfo, Joel Bravo, Paola Carvajal, Nora Silva, Claudia Godoy, Jocelyn Garcia-Sesnich, Anilei Hoare, Patricia Diaz, Jorge Gamonal, Alicia Morales, Alessandro Gandolfo, Joel Bravo, Paola Carvajal, Nora Silva, Claudia Godoy, Jocelyn Garcia-Sesnich, Anilei Hoare, Patricia Diaz, Jorge Gamonal

Abstract

The aim of this double-blind, placebo-controlled and parallel- arm randomized clinical trial was to evaluate the effects of Lactobacillus rhamnosus SP1-containing probiotic sachet and azithromycin tablets as an adjunct to nonsurgical therapy in clinical parameters and in presence and levels of Tannerella forsythia, Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans. Forty-seven systemically healthy volunteers with chronic periodontitis were recruited and monitored clinically and microbiologically at baseline for 3, 6 and 9 months after therapy. Subgingival plaque samples were collected from four periodontal sites with clinical attachment level ≥1 mm, probing pocket depth ≥4 mm and bleeding on probing, one site in each quadrant. Samples were cultivated and processed using the PCR technique. Patients received nonsurgical therapy including scaling and root planing (SRP) and were randomly assigned to a probiotic (n=16), antibiotic (n = 16) or placebo (n = 15) group. L. rhamnosus SP1 was taken once a day for 3 months. Azithromycin 500mg was taken once a day for 5 days. All groups showed improvements in clinical and microbiological parameters at all time points evaluated. Probiotic and antibiotic groups showed greater reductions in cultivable microbiota compared with baseline. The placebo group showed greater reduction in number of subjects with P. gingivalis compared with baseline. However, there were no significant differences between groups. The adjunctive use of L. rhamnosus SP1 sachets and azithromycin during initial therapy resulted in similar clinical and microbiological improvements compared with the placebo group.

Figures

Figure 1. Flowchart of the study design
Figure 1. Flowchart of the study design

References

    1. Aas JA, Paster BJ, Stokes LN, Olsen I, Dewhirst FE. Defining the normal bacterial flora of the oral cavity. J Clin Microbiol. 2005;43(11):5721–5732.
    1. Coats SR, To TT, Jain S, Braham PH, Darveau RP. Porphyromonas gingivalis resistance to polymyxin B is determined by the lipid A 4'-phosphatase, PGN_0524. Int J Oral Sci. 2009;1(3):126–135.
    1. Díaz-Zúñiga J, Yáñez-Figueroa J, Melgar-Rodríguez S, Álvarez-Rivas C, Rojas-Lagos L, Vernal-Astudillo R. Virulence and variability on Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans and their association to periodontitis. Rev Clin Periodoncia Implantol Rehabil Oral. 2012;5(1):40–45.
    1. Drisko CH. Nonsurgical periodontal therapies. Periodontol 2000. 2001;25:77–88.
    1. Gajardo M, Silva N, Gomez L, Leon R, Parra B, Contreras A, et al. Prevalence of periodontopathic bacteria in aggressive periodontitis patients in a Chilean population. J Periodontol. 2005;76(2):289–294.
    1. Gamonal J, Mendoza C, Espinoza I, Munoz A, Urzua I, Aranda W, et al. Clinical attachment loss in Chilean adult population: first Chilean national dental examination survey. J Periodontol. 2010;81(10):1403–1410.
    1. Gomi K, Yashima A, Iino F, Kanazashi M, Nagano T, Shibukawa N, et al. Drug concentration in inflamed periodontal tissues after systemically administered azithromycin. J Periodontol. 2007;78(5):918–923.
    1. Haffajee AD, Socransky SS, Patel MR, Song X. Microbial complexes in supragingival plaque. Oral Microbiol Immunol. 2008;23(3):196–205.
    1. Haffajee AD, Socransky SS, Gunsolley JC. Systemic antiinfective periodontal therapy. A systematic review. Ann Periodontol. 2003;8(1):115–181.
    1. Han B, Emingil G, Ozdemir G, Tervahartiala T, Vural C, Atilla G, et al. Azithromycin as an adjunctive treatment of generalized severe chronic periodontitis: clinical, microbiologic, and biochemical parameters. J Periodontol. 2012;83(12):1480–1491.
    1. Herrera D, Alonso B, Leon R, Roldan S, Sanz M. Antimicrobial therapy in periodontitis: the use of systemic antimicrobials against the subgingival biofilm. J Clin Periodontol. 2008;35(8) Suppl:45–66.
    1. Hincapie JP, Castrillon CA, Yepes FL, Roldan N, Becerra MA, Moreno SM, et al. Microbiological effects of periodontal therapy plus azithromycin in patients with diabetes: results from a randomized clinical trial. Acta Odontol Latinoam. 2014;27(2):89–95.
    1. Laleman I, Yilmaz E, Ozcelik O, Haytac C, Pauwels M, Herrero ER, et al. The effect of a streptococci containing probiotic in periodontal therapy: a randomized controlled trial. J Clin Periodontol. 2015;42(11):1032–1041.
    1. Martande SS, Pradeep AR, Singh SP, Kumari M, Naik SB, Suke DK, et al. Clinical and microbiological effects of systemic azithromycin in adjunct to nonsurgical periodontal therapy in treatment of Aggregatibacter actinomycetemcomitans associated periodontitis: a randomized placebo-controlled clinical trial. J Investig Clin Dent. 2016;7(1):72–80.
    1. Mayanagi G, Kimura M, Nakaya S, Hirata H, Sakamoto M, Benno Y, et al. Probiotic effects of orally administered Lactobacillus salivarius WB21-containing tablets on periodontopathic bacteria: a double-blinded, placebo-controlled, randomized clinical trial. J Clin Periodontol. 2009;36(6):506–513.
    1. Morales A, Carvajal P, Silva N, Hernandez M, Godoy C, Rodriguez G, et al. Clinical effects of Lactobacillus rhamnosus in non-surgical treatment of chronic periodontitis: a randomized placebo-controlled trial with 1-year follow-up. J Periodontol. 2016;87(8):944–952.
    1. Muniz FW, Oliveira CC, Carvalho RS, Moreira MM, Moraes ME, Martins RS. Azithromycin: a new concept in adjuvant treatment of periodontitis. Eur J Pharmacol. 2013;705(1-3):135–139.
    1. Oteo A, Herrera D, Figuero E, O'Connor A, Gonzalez I, Sanz M. Azithromycin as an adjunct to scaling and root planing in the treatment of Porphyromonas gingivalis-associated periodontitis: a pilot study. J Clin Periodontol. 2010;37(11):1005–1015.
    1. Pamer EG. Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens. Science. 2016;352(6285):535–538.
    1. Sampaio E, Rocha M, Figueiredo LC, Faveri M, Duarte PM, Gomes Lira EA, et al. Clinical and microbiological effects of azithromycin in the treatment of generalized chronic periodontitis: a randomized placebo-controlled clinical trial. J Clin Periodontol. 2011;38(9):838–846.
    1. Sefton AM, Maskell JP, Beighton D, Whiley A, Shain H, Foyle D, et al. Azithromycin in the treatment of periodontal disease: effect on microbial flora. J Clin Periodontol. 1996;23(11):998–1003.
    1. Shimauchi H, Mayanagi G, Nakaya S, Minamibuchi M, Ito Y, Yamaki K, et al. Improvement of periodontal condition by probiotics with Lactobacillus salivarius WB21: a randomized, double-blind, placebo-controlled study. J Clin Periodontol. 2008;35(10):897–905.
    1. Socransky SS, Haffajee AD, Cugini MA, Smith C, Kent RL., Jr Microbial complexes in subgingival plaque. J Clin Periodontol. 1998;25(2):134–144.
    1. Sun J, Sundsfjord A, Song X. Enterococcus faecalis from patients with chronic periodontitis: virulence and antimicrobial resistance traits and determinants. Eur J Clin Microbiol Infect Dis. 2012;31(3):267–272.
    1. Teanpaisan R, Piwat S, Dahlen G. Inhibitory effect of oral Lactobacillus against oral pathogens. Lett Appl Microbiol. 2011;53(4):452–459.
    1. Tekce M, Ince G, Gursoy H, Dirikan Ipci S, Cakar G, Kadir T, et al. Clinical and microbiological effects of probiotic lozenges in the treatment of chronic periodontitis: a 1-year follow-up study. J Clin Periodontol. 2015;42(4):363–372.
    1. Teughels W, Durukan A, Ozcelik O, Pauwels M, Quirynen M, Haytac MC. Clinical and microbiological effects of Lactobacillus reuteri probiotics in the treatment of chronic periodontitis: a randomized placebo-controlled study. J Clin Periodontol. 2013;40(11):1025–1035.
    1. Van der Velden U. Purpose and problems of periodontal disease classification. Periodontol 2000. 2005;39:13–21.
    1. Vivekananda MR, Vandana KL, Bhat KG. Effect of the probiotic Lactobacilli reuteri (Prodentis) in the management of periodontal disease: a preliminary randomized clinical trial. J Oral Microbiol. 2010;2 doi: 10.3402/jom.v2i0.5344.
    1. Yashima A, Gomi K, Maeda N, Arai T. One-stage full-mouth versus partial-mouth scaling and root planing during the effective half-life of systemically administered azithromycin. J Periodontol. 2009;80(9):1406–1413.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit